Immatics N.V. (NASDAQ: IMTX)

Immatics N.V., a clinical-stage biotechnology company, is dedicated to the development of T cell receptor- (TCR-) based immunotherapies for the treatment of patients with solid tumors. The company's primary products include ACTengine IMA203, ACTengine IMA203CD8, and TCER IMA401, and it generates revenue through the development and commercialization of its TCR-based immunotherapies.

Immatics operates in the biotechnology industry and focuses on the development of TCR-T and TCER-based immunotherapies. The TCR-T segment is dedicated to the development of autologous TCR-engineered T cells, which are designed to recognize and target specific cancer targets on tumor cells. The TCER segment focuses on the development of T cell engaging receptors, which are designed to recognize and target specific cancer targets on tumor cells. The TCR-T segment is further divided into two sub-segments: ACTengine IMA203 and ACTengine IMA203CD8. ACTengine IMA203 is a TCR-T product candidate that targets the PRAME antigen, which is frequently expressed in solid tumors. ACTengine IMA203CD8 is a TCR-T product candidate that targets the PRAME antigen and is designed to be used in combination with a CD8αβ co-receptor. The TCER segment is focused on the development of T cell engaging receptors that target specific cancer targets on tumor cells, with the lead TCER product candidate, IMA401, targeting the MAGEA4/8 antigen, which is frequently expressed in solid tumors.

Immatics has a strong competitive position in the TCR-based immunotherapy market, with a pipeline of product candidates that have shown promising results in clinical trials. The company's ACTengine IMA203 product candidate has shown a confirmed overall response rate (cORR) of 50% in patients with cutaneous melanoma, and the company plans to initiate a registration-enabling randomized Phase 2/3 trial in 2024. Immatics' customers include patients with solid tumors, such as melanoma, ovarian cancer, and lung cancer, who are in need of effective and innovative treatments. The company's products are designed to be used in combination with other cancer therapies, such as checkpoint inhibitors, to enhance their efficacy and reduce the risk of resistance.

Immatics' technology platforms, XPRESIDENT and XCEPTOR, enable the discovery and development of TCR-based immunotherapies. XPRESIDENT is a proprietary target and TCR discovery platform that identifies and validates cancer targets and TCRs. XCEPTOR is a proprietary TCR identification platform that enables the discovery and engineering of TCRs with high affinity and specificity. Immatics has a strategic collaboration with Bristol Myers Squibb to develop next-generation allogeneic gamma delta TCR-T/CAR-T programs with enhanced persistence, safety, and potency. The company has also partnered with Editas Medicine to develop CRISPR gene editing technology for the development of TCR-based immunotherapies.

In terms of intellectual property, Immatics owns a number of patents and patent applications related to its TCR-based immunotherapies, including patents covering the composition of matter of its product candidates, as well as patents related to its technology platforms. The company has also applied for several trademarks, including the trademarks "Immatics", "XPRESIDENT", "TCER", "XCEPTOR", "ACTallo", and "ACTengine". Immatics has forged strategic collaborations with several biotech and pharmaceutical companies, including Moderna, Editas Medicine, and Bristol Myers Squibb. The company has also entered into a license agreement with Genmab to develop and commercialize its TCR Bispecific candidate, IMA401.